keyword
MENU ▼
Read by QxMD icon Read
search

PUVA eczema

keyword
https://www.readbyqxmd.com/read/27910127/treatment-of-severe-chronic-hand-eczema-results-from-a-uk-wide-survey
#1
I L Smith, S Brown, J Nixon, F C Cowdell, S Ersser, C Fernandez, M Goodfield, C M Green, P Hampton, J T Lear, C H Smith, L Sunderland, S Tubeuf, M Wittmann
Treatment of severe hand eczema (HE) that is resistant to topical potent corticosteroid treatment is challenging. In 2013, we surveyed 194 UK dermatologists to obtain information about their usual treatment pathways to inform the choice of the comparator in a trial of alitretinoin in severe HE (ALPHA trial); the results indicated that the treatment approaches favoured by UK dermatologists differ. Psoralen combined with ultraviolet A (PUVA) and alitretinoin were identified as the most frequent first-line treatment options for hyperkeratotic HE, whereas oral corticosteroids were identified as the most frequent first-line treatment for vesicular HE, followed by PUVA and alitretinoin...
December 2, 2016: Clinical and Experimental Dermatology
https://www.readbyqxmd.com/read/26592977/medical-psychological-and-socio-economic-implications-of-chronic-hand-eczema-a-cross-sectional-study
#2
S Cazzaniga, B K Ballmer-Weber, N Gräni, P Spring, A Bircher, M Anliker, A K Sonntag, P Piletta, C Huber, L Borradori, T Diepgen, C Apfelbacher, D Simon
BACKGROUND: Hand eczema (HE) is a common skin disease with major medical psychological and socio-economic implications. Onset and prognosis of HE are determined by individual as well as environmental factors. So far, most epidemiological data on HE have been reported from Scandinavian and recently German studies. OBJECTIVE: To investigate the characteristics and medical care of patients with chronic HE (CHE) in Switzerland, and identify risk factors. METHODS: In this cross-sectional study, data from patients with chronic HE were obtained by means of medical history, dermatological examination and patient questionnaires...
April 2016: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/26515832/guidelines-for-bath-puva-bathing-suit-puva-and-soak-puva
#3
REVIEW
Sathish B Pai, Shricharith Shetty
BACKGROUND: The aim of these guidelines is to encourage dermatologists to use bath psoralen plus ultraviolet A (PUVA), bathing suit PUVA and soak PUVA in the treatment of psoriasis vulgaris and other conditions. METHODS: Evidence was collected using searches of the PubMed, MEDLINE and COCHRANE databases using the keywords "bath PUVA," "soak PUVA," "bathing suit PUVA" and "turban PUVA." Only publications in English were reviewed. RESULTS: One hundred and thirty-eight studies were evaluated, 57 of which fulfilled the criteria for inclusion...
November 2015: Indian Journal of Dermatology, Venereology and Leprology
https://www.readbyqxmd.com/read/26464123/ultraviolet-phototherapy-for-cutaneous-diseases-a-concise-review
#4
R Vangipuram, S R Feldman
Phototherapy is the use of non-ionizing radiation, primarily in the ultraviolet spectrum, to treat disease. In dermatology, ultraviolet (UV) phototherapy remains an established, lower cost, and often preferred option for many common skin conditions, despite the introduction of newer potent biologics. This article introduces a principal therapeutic modality in the treatment of psoriasis, atopic dermatitis (eczema), vitiligo, and morphea among other diseases where oral manifestations may be present, providing basic information about the use of UVA, UVB, and PUVA...
May 2016: Oral Diseases
https://www.readbyqxmd.com/read/25876642/a-severe-case-of-recalcitrant-pompholyx
#5
Jeewanjit Gill, Melanie Pratt
BACKGROUND: Pompholyx is an inflammatory vesiculobullous skin disease of the hands and feet belonging to the spectrum of eczema. OBJECTIVE: To report a severe case of pompholyx, its clinical presentation, and its management. METHODS: A medical chart review was conducted on a patient with this condition. RESULTS: The patient was patch tested according to the North American Contact Dermatitis Group (NACDG) Standard Screening Series, and results were negative...
September 2015: Journal of Cutaneous Medicine and Surgery
https://www.readbyqxmd.com/read/25809797/phototherapy-in-the-elderly
#6
J B Powell, J E Gach
BACKGROUND: Elderly patients present with a unique spectrum of dermatoses that pose particular management opportunities and challenges, which will be increasingly encountered in dermatological practice. The skin of elderly patients differs from that of younger patients not only in appearance but also in structure, physiology and response to ultraviolet (UV) radiation. However, little is known about the safety and efficacy of phototherapy in elderly patients and how phototherapy is currently being utilized to treat them...
August 2015: Clinical and Experimental Dermatology
https://www.readbyqxmd.com/read/25566890/phototherapy-for-atopic-dermatitis
#7
REVIEW
Sunil Dogra, Rahul Mahajan
BACKGROUND: The aim of these guidelines is to review the available published literature regarding the effectiveness of phototherapy and photochemotherapy in atopic dermatitis and put forward recommendations regarding their use in atopic dermatitis. MATERIALS AND METHODS: A literature search was performed to collect data from PubMed, EMBASE, and the Cochrane Library published till March 2014. Keywords used were "phototherapy", "photochemotherapy", "NB-UVB", "BBUVB", "PUVA", "UVA1", "atopic dermatitis", and "atopic eczema"...
January 2015: Indian Journal of Dermatology, Venereology and Leprology
https://www.readbyqxmd.com/read/25386313/psoralen-plus-ultraviolet-a-puva-soaks-and-uvb-tl01-treatment-for-chronic-hand-dermatoses
#8
Lisbeth Jensen, Anette Stensgaard, Klaus Ejner Andersen
Chronic eczematous hand dermatoses with and without contact allergies are complex diseases, which makes it a challenge to select the best treatment and obtain an optimal patient experience and a satisfactory treatment result. The aim of this study was to evaluate retrospectively the clinical effect and patient experience of local treatment with psoralen plus ultraviolet A (PUVA) soaks and TL01 phototherapy for severe chronic hand dermatoses, and also to evaluate the quality of life for the subgroup of patients with allergic contact dermatitis including Compositae allergy...
January 2, 2012: Dermatology Reports
https://www.readbyqxmd.com/read/23420314/randomized-controlled-observer-blinded-treatment-of-chronic-foot-eczema-with-iontophoresis-and-bath-puva
#9
RANDOMIZED CONTROLLED TRIAL
Ron A Tupker, Pieter J Coenraads, Pieter Zanen, Marie Louise A Schuttelaar
The aim of this study was to investigate the effect of iontophoresis combined with local psoralen plus ultraviolet A (PUVA) therapy in chronic foot eczema. A randomized, observer-blinded, multi-centre study was conducted in 48 patients with chronic moderate-to-severe foot eczema randomized to one of 3 groups: In the iontophoresis group local bath-PUVA was preceded by iontophoresis. In the PUVA group only local PUVA was given. The corticosteroid group was treated with fluticasone. All treatments were given for 8 weeks, with an 8-week follow-up period...
July 6, 2013: Acta Dermato-venereologica
https://www.readbyqxmd.com/read/22924689/is-there-still-a-role-for-psoralen-ultraviolet-a-in-the-treatment-of-chronic-hand-eczema
#10
D Al-Ismail, C Edwards, A Anstey
No abstract text is available yet for this article.
October 2012: Clinical and Experimental Dermatology
https://www.readbyqxmd.com/read/22738245/retrospective-long-term-follow-up-in-patients-with-chronic-palmoplantar-dermatoses-after-good-response-to-bath-puva-therapy
#11
Agnes Bretterklieber, Franz J Legat, Peter Wolf, Angelika Hofer
BACKGROUND: Numerous studies have confirmed the short-term effectiveness of 8-methoxypsoralen bath PUVA therapy in patients with chronic palmoplantar dermatoses; however, little is known about long-term results. PATIENTS AND METHODS: In this retrospective study we examined the long-term results in 79 patients (mean age: 48 years) with chronic palmoplantar dermatoses who were treated with bath PUVA three times a week over an 8-year period. A good clinical response (a reduction of more than 50% of the skin lesions) occurred after a mean of 23 treatments and a mean cumulative UVA dose of 39 J/cm(2) in 51 patients (65%)...
November 2012: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/22268857/psoriasis-an-evidence-based-update-report-of-the-9th-evidenced-based-update-meeting-12-may-2011-loughborough-uk
#12
P De Mozzi, G A Johnston, A B Alexandroff
The Centre of Evidence Based Dermatology, University of Nottingham, U.K. holds an annual Evidence Based Update (EBU) Meeting focused on important dermatological topics, which have in the past included eczema, urticaria, blistering disorders, skin infections, skin cancer and hair disorders. These one-day meetings aim to summarize the most recent evidence in the form of systematic reviews and recently completed clinical trials. This year, the 9th EBU meeting took place in Loughborough, U.K. on 12 May 2011 and was devoted to psoriasis...
February 2012: British Journal of Dermatology
https://www.readbyqxmd.com/read/21940018/-eccema-herpeticum
#13
Cristina Mauleón Fernández, Catiana Silvente San Nicasio, Marta Valdivielso Ramos, Eva Chavarría Mur
No abstract text is available yet for this article.
April 14, 2012: Medicina Clínica
https://www.readbyqxmd.com/read/20507802/alitretinoin-for-the-treatment-of-severe-chronic-hand-eczema
#14
REVIEW
M Paulden, M Rodgers, S Griffin, R Slack, S Duffy, J R Ingram, N Woolacott, M Sculpher
This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of alitretinoin for the treatment of adults with severe chronic hand eczema refractory to topical steroid treatment in accordance with the licensed indication, based upon the evidence submission from Basilea Pharmaceuticals Ltd to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal process. The clinical evidence came from a single placebo-controlled randomised controlled trial of daily treatment with alitretinoin for 12-24 weeks, with follow-up for a further 24 weeks, in patients with severe chronic hand eczema (CHE) unresponsive to topical steroids...
May 2010: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/20131924/alitretinoin-for-severe-chronic-hand-eczema-a-nice-single-technology-appraisal
#15
REVIEW
Mark Rodgers, Susan Griffin, Mike Paulden, Russell Slack, Steven Duffy, John R Ingram, Nerys Woolacott, Mark Sculpher
The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of alitretinoin (Basilea Pharmaceuticals Ltd, Basel, Switzerland) to submit evidence for the clinical and cost effectiveness of this drug for the treatment of patients with severe chronic hand eczema (CHE), as part of the Institute's single technology appraisal (STA) process. The Centre for Reviews and Dissemination and the Centre for Health Economics at the University of York were commissioned to act as the Evidence Review Group (ERG)...
2010: PharmacoEconomics
https://www.readbyqxmd.com/read/20066389/predictive-testing-of-the-melanocortin-1-receptor-for-skin-cancer-and-photoaging
#16
REVIEW
C W Lynde, S Sapra
Genetic predisposition to melanoma and nonmelanoma skin cancer extends far beyond the Fitzpatrick phenotype classification scheme. Specific alleles of the gene that codes for the malnocortin 1 receptor are predictive of skin cancer risk independent of skin type and hair color. The ability to identify high risk patients independent of the red hair phenotype may help to modify routine sun and skin monitoring behaviors. In addition, as this increased skin cancer risk is likely due to impaired UVA and UVB defence mechanisms, consideration of genetic predisposition may also be appropriate for patients undergoing psoralen + UVA (PUVA) or UVB treatments for various cutaneous disorders, such as psoriasis, eczema, and vitiligo...
January 2010: Skin Therapy Letter
https://www.readbyqxmd.com/read/19827442/-treatment-for-chronic-hand-eczema
#17
REVIEW
S Molin, T Ruzicka
No abstract text is available yet for this article.
May 7, 2009: MMW Fortschritte der Medizin
https://www.readbyqxmd.com/read/19292787/oral-vs-bath-puva-using-8-methoxypsoralen-for-chronic-palmoplantar-eczema
#18
RANDOMIZED CONTROLLED TRIAL
Stanislava Tzaneva, Harald Kittler, Christiane Thallinger, Herbert Hönigsmann, Adrian Tanew
BACKGROUND: Both oral and bath PUVA with 8-methoxypsoralen (8-MOP) have been shown to be effective in the treatment of chronic palmoplantar eczema. However, most studies were retrospective and did not include longer follow-up periods. AIM: To compare the therapeutic efficacy, tolerability and duration of remission after oral vs. bath PUVA using 8-MOP in patients with chronic palmoplantar eczema. METHODS: Twenty-nine patients were randomly allocated to treatment with oral or bath PUVA...
April 2009: Photodermatology, Photoimmunology & Photomedicine
https://www.readbyqxmd.com/read/18712324/-ultraviolet-therapy-in-patients-with-chronic-hand-eczema
#19
REVIEW
H Stege
Treatment of hand eczema is dominated by the administration of topical glucocorticosteriods. If topical treatment fails, the best second-line option is ultraviolet (UV) therapy alone or as combination therapy. UVB and PUVA (psoralen plus UVA) therapy is effective and has relatively few side effects. Due to the localized nature of the disease, topical PUVA therapy is preferable to systemic PUVA treatment. Among the topical methods, cream PUVA therapy is simple, safe and highly effective. Recent clinical studies have demonstrated the therapeutic efficacy of a new retinoid called alitretinoin, a 9-cis-retinoic acid...
September 2008: Der Hautarzt; Zeitschrift Für Dermatologie, Venerologie, und Verwandte Gebiete
https://www.readbyqxmd.com/read/18491990/pompholyx-what-s-new
#20
REVIEW
Uwe Wollina
BACKGROUND: Pompholyx is a chronic relapsing inflammatory vesicobullous skin disease of the hands and feet belonging to the spectrum of eczema. Established treatments, both topical and systemic, are limited in efficacy, risk:benefit ratio and prevention of further relapses. New treatment options are needed. OBJECTIVE: The article will discuss new treatment options, in particular for cheiropompholyx. METHODS: A MEDLINE and ClinicalTrials.gov research has been conducted and publications about new and emerging treatments for pompholyx have been analysed...
June 2008: Expert Opinion on Investigational Drugs
keyword
keyword
115909
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"